Abstract
The clinical course of B-cell chronic lymphocytic leukemia (B-CLL) is variable and novel biological parameters need to be added to the clinical staging systems to predict an indolent or aggressive outcome. We investigated the 70-kD zeta-associated protein (ZAP-70), CD38, soluble CD23 (sCD23) and cytogenetics in 289 B-CLL patients. Both a shorter progression free survival (PFS) and overall survival (OS) were observed in ZAP-70 + unmutated had a longer PFS. Furthermore, ZAP-70 positivity was associated with a shorter PFS both within normal karyotype (P=0.00006) and within the poor risk cytogenetic subset (P=0.02).
The predictive value of ZAP-70 expression was confirmed in multivariate analysis. Thus, ZAP-70 protein determined by flow cytometry improves the prognostic significance of cytogenetics and appears to be a better predictor of outcomes than IgV H gene mutational status. On this line, we recommend and are also interested in conducting a prospective randomized trial of early intervention versus observation for ZAP-70 + patients.
Introduction
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and is characterized by the accumulation of monoclonal CD5 + B cells with the appearance of small mature lymphocytes. 1 One the most intriguing features of the disease is its clinical heterogeneity with patients progressing rapidly with early death, whereas others exhibit a more stable non progressive disease lasting many years. Thus, it is more important than ever to develop sensitive stratification parameters to identify patients with poor prognosis. likely, selected by different, yet unidentified, antigens. 5 On average patients with M IgV H genes have a more indolent clinical course than those with the unmutated phenotype and have a longer survival. 6, 7 Investigations using DNA microarrays have shown that CLL cells exhibit a characteristic geneexpression profile in which the expression of small subgroup of genes, including those encoding ZAP-70, IM1286077 and C-type lectin, correlates with the mutational status of IgV H genes. 8, 9 ZAP-70, a member of the Syk-ZAP-70 protein tyrosine kinase family, is normally expressed in T and natural killer cells and has a critical role in initiation of T-cell signalling. 10, 11 Recent studies have found that ZAP-70 is associated with enhanced signalling by the cell-surface immunoglobulin receptor in CLL B cells 12 and that measurement of ZAP-70 can serve as a surrogate for mutational status of IgV H . 13 Moreover, ZAP-70 protein may be conveniently measured by flow-cytometry, in contrast to the technically demanding IgV H analysis. 14 In a larger series of patients, Rassenti et al 15 have shown that an increased expression of ZAP-70 by CLL is a only.
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CD38 expression also has been suggested as a surrogate marker for the mutational status in B-CLL. 6 At present, both parameters are regarded as independent prognostic variables in B-CLL. 16 Detection of CD38 cell surface expression can be easily performed by flow cytometry in the general laboratory.
Genetic studies using chromosome analysis or interphase fluorescence in situ hybridization (FISH) have identified recurring abnormalities with prognostic significance. Patients with a normal karyotype or deletion of 13q14 as the sole genetic abnormality have a better prognosis than those with a complex karyotype or deletion 11q23 or 17p13. 17 In a large study these deletions were associated with a shorter overall survival.
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In this study, ZAP-70, CD38, soluble CD23 (sCD23), mutational status and genomic aberrations in relation to other laboratory parameters and clinical information were examined in a large series of B-CLL patients.
In collected on a single day for each patient and were evaluated at diagnosis or before disease progression or before any chemotherapeutic approach. We tried to set empirically various cut-off points for each biological variable (ZAP-70, CD38, sCD23) and the selected thresholds were sufficient to predict progression and survival, identifying accurately patients at poor prognosis.
Moreover, we applied a discriminant function analysis based on the squared Mahalanobis distances of each case from its group centroids (ZAP-70, CD38, sCD23) to verify the selected cut-points. 
Cellular immunophenotypic analysis
The following antibody conjugates were used: anti-CD23-PE, anti-CD5-FITC, anti-CD38-PE, anti-CD19-APC, anti-CD45-FITC, anti-CD14-PE, anti-CD95-PE, anti-CD10-FITC (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA). Peripheral blood mononuclear cells were analyzed for surface expression of CD19/CD5/CD38 and CD19/CD5/CD23 by triple color immunofluorescence, as described elsewhere. 
Enzyme-linked immunosorbent assays
Soluble CD23 (sCD23) immunoenzymometric assay was performed as described elsewhere. 19 The threshold of positivity was set at sCD23 value of more than 70 U/mL.
Interphase FISH
Separate hybridisations were carried out for loci on chromosome 11, 12, 13 and 17. For chromosomes 11 (q23), 13 and 17 commercial probes (ATM-2, Rb-1 and p53, respectively) were used (Vysis, Inc, London, United Kingdom). An alpha satellite DNA probe CEP12, directly labelled with SpectrumGreen, was used to detect aneuploidy of chromosome 12. LSIp53, labelled with SpectrumOrange (Vysis), was used to evaluate chromosome deletion at 17p13.1. We used peripheral blood lymphocytes, which were separated by density gradient centrifugation, treated with hypotonic solution (KCl) and fixed with methanol-acetic acid. Then the slides were aged for 20 min at 80°C on a hot plate and dehydrated for 2 min in 70%, 80% and 100% ethanol and air dried. Gene frames were applied to dried slides in order to mark and separate the hybridisation areas of single probes. Slides were placed on a hot plate at 37°C and 5 μl of each probe buffer solution was applied inside the area of the slides delineated by the frame. After, the slides were sealed with a 22x22 mm gene-frame plastic coverslip and placed in the Vysis Hybrite TM machine.
only.
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IgV H mutation analysis
Total RNA was extracted and reverse-transcribed as previously reported. 20 The resulting cDNAs, checked for first strand synthesis, 21 were amplified using a mixture of sense primers annealing either to the V H 1 through V H 6 leader sequences or to the 5' end of V H 1-V H 6 FR1, as reported. The proportion of B cells expressing CD38 varied from 0 to 87% and the threshold was set at 30%, as previously reported. 19 Based on this cut-off value, 67 patients (23%) were CD38 + and 222 patients (77%) were CD38 -. In order to test the stability of CD38 over time, we further analysed sequential samples from 65 patients (range 3-8 for patient) over periods ranging from 2 to 45 months. In 58 of 65 cases (89%) slight differences (<10%) were detected. A total of 7 (11%) cases showed a variation higher than 10%. However, no patient crossed the used 30% cut-off.
Finally, sCD23 was higher than 70 U/ml in 82 patients (32.2%) and lower than 70 in 172 patients (67.7%). Considering the possibility that also sCD23 levels may be unstable during disease, we analysed samples from 85 patients over periods ranging from 2 to 66 months. In 75 out of 85 cases (88%) we detected ignorable differences (<15%). A total of 10 (12%) cases showed variations higher than 15%, but the selected threshold (70 U/ml) was never crossed.
For Table 2 ) and in CD38 -patients (61% vs 19%, P=0.00004, Table 2 ).
A significant shorter PFS was observed in ZAP-70 + patients (0% vs 59% at 13 years, P<0.00001, Figure 2A ), in CD38 + patients (8% vs 42% at 14 years, P<0.00001, Figure 2B ) and in sCD23 >70 U/ml cases (0% vs 55% at 13 years, P<0.00001, Figure 2C ). showed a significant longer PFS (P<0.00001). (C) sCD23 levels lower than 70 U/ml characterized pts with a longer PFS (P<0.00001).
Likewise, a shorter OS was found in ZAP-70 + patients (16% vs 86% at 18 years, P<0.00001, Figure 3A ), in CD38 + patients (0% vs 73% at 18 years, P=0.00001, Figure 3B ) and, less significantly, in sCD23 + cases (43% vs 79% at 14 years, P=0.013, Figure 3C ). Less significantly, a longer OS was found in pts with sCD23 levels lower than 70 U/ml (C) (P=0.013).
Interestingly, the simultaneous positivity or negativity for ZAP-70 and CD38 identified two subsets of patients, the former with a worse prognosis and the latter with a better prognosis with regard to both PFS (8% vs 60% at 12 years, P<0.00001, Figure 4A ) and OS (18% vs 94% at 16 years, P=0.00002, Figure 4B Figure 4C ) and OS (20% vs 94% at 13 years, P=0.00004, Figure 4D Figure 5A and 5B).
Interestingly, within the ZAP-70 -subset (185 of 289 patients, 64%) patients with sCD23>70 U/ml levels had a significant shorter PFS, as compared to cases with sCD23 lower than 70 U/ml cut-off (21% vs 76% at 10 years, P=0.0005, Figure 5C ). With regard to clonal genomic aberrations, a significant shorter PFS was observed in patients with prognostically unfavorable aberrations, such as 17p-, 11q-and trisomy 12, which were pooled together and defined as a poor risk cytogenetic subset (n=30), vs normal karyotype patients (n=85, 7% vs 39% at 12 years, P=0.004, Figure 6A ). The 13q-patients (n=42) showed an intermediate outcome (22% at 12 years).
To further explore the clinical impact of ZAP-70 expression among different cytogenetic groups, we investigated its expression within the normal karyotype and the poor risk cytogenetic subsets.
As a matter of fact, ZAP-70 positivity was significantly associated with a shorter PFS both within normal karyotype (14% vs 67% at 10 years, P=0.00006, Figure 6B ) and within the poor risk subset (0% vs 29% at 10 years, P=0.02, Figure 6C ).
For Finally, we performed a multivariate Cox regression analysis of PFS and OS, including as covariates, age < or > 60 years, modified Rai stages, β 2 -microglobulin, sCD23, CD38 and ZAP-70.
With regard to PFS, ZAP-70, sCD23 and modified Rai stages were confirmed to be independent prognostic factors (Table 3) . Concerning OS, only ZAP-70 was an independent prognostic factor, while CD38 showed a trend toward a statistical significance (Table 4) . 
Discusssion
ZAP-70 expression, determined by flow cytometry, has already been identified as a significant predictor of disease progression and overall survival in B-CLL. [13] [14] [15] 26, 27 We used a well-standardized flow cytometric methodology 13 We show here that ZAP-70 expression was significantly correlated with CD38 antigen: both these two markers are more highly expressed in UM IgV H CLL and are consistent with a more activated only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From phenotype. Ongoing antigen-mediated activation of the leukemic cells through the BCR is suggested by the presence of cellular activation markers on the cell surface. 30 Probably, the B-CLL subset expressing ZAP-70 and CD38 may reflect ongoing in vivo stimulation, thereby explaining the more aggressive disease course observed in these patients. 8 Chen et al However, the simultaneous information of both ZAP-70 level and IgV H mutational status still provides more useful prognostic information given a certain degree of discordance between these two prognosticators (from 5% to 23%), as underscored in recent studies. 32 We obtained that 20%
of the results of the two methods were discordant. Our discordance rate was greater than 5 to 6 percent reported by Crespo et al 13 Furthermore, complete response to fludarabine as initial therapy was significantly correlated with ZAP-70 percentages (P=0.0008), as well as with CD38 expression (P=0.0001), confirming that these biological markers may be used to predict the chemosensitivity of B-CLL patients.
We demonstrated that ZAP-70 positivity was significantly related to an unfavorable cinical course as regards both to PFS (P<0.00001) and OS (P<0.00001) on a large series of B-CLL patients in accordance with the studies by Crespo et al, 13 Orchard et al 14 and Rassenti et al. 15 These important results were also confirmed by restricting the analysis to patients initially presenting in Figure 4 .
Again, almost all discordant patients were ZAP-70 + and M IgV H suggesting that ZAP-70 may be a better predictor of outcomes than Ig-mutation status. 15, 35 Interestingly, in our study we described a novel clinical preliminary observation that the two small Up today, there are not large studies on the combined prognostic significance of ZAP-70 and cytogenetics in B-CLL. 37 In our study, ZAP-70 protein confirmed a predictive power distinguishing patients who have early PFS or short OS within normal karyotype and poor risk cytogenetic subsets, where progression was heterogeneous.
The independent prognostic effect of ZAP-70 expression on the clinical outcome of B-CLL patients was finally corroborated by the multivariate analysis with regard both to PFS and OS (Table 3 and 4 ).
In conclusion, our study demonstrates that the increased expression of ZAP-70 by CLL cells is a more significant predictor of disease progression than the presence of CD38 and sCD23.
Moreover, ZAP-70 was able to predict a different outcome within interphase cytogenetic groups.
In addition, combined analysis of ZAP-70 and CD38 or ZAP-70 and IgV H status allowed us to identify discordant subsets of patients in which the presence of ZAP-70 alone was sufficient to define a poor prognosis. These results suggest a superior prognostic role of ZAP-70 over CD38
and IgV H mutational status. Importantly, this parameter can be determined easily and rapidly by flow cytometry, even though further studies are required to develop a standardized flow cytometry protocol. Finally, because ZAP-70 expression appears to be stable over time, it should be used at the time of diagnosis to identify patients at increased risk for early disease progression. 
